The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Melanoma Skin Cancer Diagnostic Testing-Global Market Insights and Sales Trends 2025
Synopsis
Melanoma skin cancer is the most dangerous type of skin cancer. Development of defective DNA due to exposure to the ultraviolet radiation from sunlight or tanning beds leads to develop melanoma skin cancer. This genetic defect triggers mutation in the cell structure resulting in rapid multiplication of cells forming a malignant tumor. These malignant tumors often originate at basal layer of epidermis which produces melanocyte type of pigment which makes most of melanoma skin cancer black or brown in color. As per skin cancer foundation, in 2018 around 178,560 cases of melanoma will be diagnosed in United States alone. Melanoma skin cancer is the least common type of skin cancer and it is curable if diagnosed early. Early melanoma skin cancer diagnostic testing plays major role future treatment regimen and possible cure for the patient.
The global Melanoma Skin Cancer Diagnostic Testing market size is expected to reach US$ 1210.4 million by 2029, growing at a CAGR of 7.9% from 2023 to 2029. The market is mainly driven by the significant applications of Melanoma Skin Cancer Diagnostic Testing in various end use industries. The expanding demands from the Hospitals, Dermatology Clinics, Diagnostic Laboratories and Others, are propelling Melanoma Skin Cancer Diagnostic Testing market. Biopsy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Imaging segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Melanoma Skin Cancer Diagnostic Testing, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Melanoma Skin Cancer Diagnostic Testing market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Melanoma Skin Cancer Diagnostic Testing market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Melanoma Skin Cancer Diagnostic Testing sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Melanoma Skin Cancer Diagnostic Testing covered in this report include Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech and Sysmex Inostics, etc.
The global Melanoma Skin Cancer Diagnostic Testing market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Myriad Genetics
Abbott Laboratories
Foundation Medicine
Pathway Genomics Corporation
Cancer Genetics
Castle Biosciences
NeoGenomics
Dermtech
Sysmex Inostics
Global Melanoma Skin Cancer Diagnostic Testing market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Melanoma Skin Cancer Diagnostic Testing market, Segment by Type:
Biopsy
Imaging
Others
Global Melanoma Skin Cancer Diagnostic Testing market, by Application
Hospitals
Dermatology Clinics
Diagnostic Laboratories
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Melanoma Skin Cancer Diagnostic Testing companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Melanoma skin cancer is the most dangerous type of skin cancer. Development of defective DNA due to exposure to the ultraviolet radiation from sunlight or tanning beds leads to develop melanoma skin cancer. This genetic defect triggers mutation in the cell structure resulting in rapid multiplication of cells forming a malignant tumor. These malignant tumors often originate at basal layer of epidermis which produces melanocyte type of pigment which makes most of melanoma skin cancer black or brown in color. As per skin cancer foundation, in 2018 around 178,560 cases of melanoma will be diagnosed in United States alone. Melanoma skin cancer is the least common type of skin cancer and it is curable if diagnosed early. Early melanoma skin cancer diagnostic testing plays major role future treatment regimen and possible cure for the patient.
The global Melanoma Skin Cancer Diagnostic Testing market size is expected to reach US$ 1210.4 million by 2029, growing at a CAGR of 7.9% from 2023 to 2029. The market is mainly driven by the significant applications of Melanoma Skin Cancer Diagnostic Testing in various end use industries. The expanding demands from the Hospitals, Dermatology Clinics, Diagnostic Laboratories and Others, are propelling Melanoma Skin Cancer Diagnostic Testing market. Biopsy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Imaging segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Melanoma Skin Cancer Diagnostic Testing, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Melanoma Skin Cancer Diagnostic Testing market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Melanoma Skin Cancer Diagnostic Testing market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Melanoma Skin Cancer Diagnostic Testing sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Melanoma Skin Cancer Diagnostic Testing covered in this report include Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech and Sysmex Inostics, etc.
The global Melanoma Skin Cancer Diagnostic Testing market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Myriad Genetics
Abbott Laboratories
Foundation Medicine
Pathway Genomics Corporation
Cancer Genetics
Castle Biosciences
NeoGenomics
Dermtech
Sysmex Inostics
Global Melanoma Skin Cancer Diagnostic Testing market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Melanoma Skin Cancer Diagnostic Testing market, Segment by Type:
Biopsy
Imaging
Others
Global Melanoma Skin Cancer Diagnostic Testing market, by Application
Hospitals
Dermatology Clinics
Diagnostic Laboratories
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Melanoma Skin Cancer Diagnostic Testing companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Melanoma Skin Cancer Diagnostic Testing
1.1 Melanoma Skin Cancer Diagnostic Testing Market Overview
1.1.1 Melanoma Skin Cancer Diagnostic Testing Product Scope
1.1.2 Melanoma Skin Cancer Diagnostic Testing Market Status and Outlook
1.2 Global Melanoma Skin Cancer Diagnostic Testing Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2018-2029)
1.4 Global Melanoma Skin Cancer Diagnostic Testing Historic Market Size by Region (2018-2023)
1.5 Global Melanoma Skin Cancer Diagnostic Testing Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Melanoma Skin Cancer Diagnostic Testing Market Size (2018-2029)
1.6.1 North America Melanoma Skin Cancer Diagnostic Testing Market Size (2018-2029)
1.6.2 Europe Melanoma Skin Cancer Diagnostic Testing Market Size (2018-2029)
1.6.3 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size (2018-2029)
1.6.4 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size (2018-2029)
1.6.5 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size (2018-2029)
2 Melanoma Skin Cancer Diagnostic Testing Market by Type
2.1 Introduction
2.1.1 Biopsy
2.1.2 Imaging
2.1.3 Others
2.2 Global Melanoma Skin Cancer Diagnostic Testing Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Melanoma Skin Cancer Diagnostic Testing Historic Market Size by Type (2018-2023)
2.2.2 Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Type (2018-2029)
3 Melanoma Skin Cancer Diagnostic Testing Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Dermatology Clinics
3.1.3 Diagnostic Laboratories
3.1.4 Others
3.2 Global Melanoma Skin Cancer Diagnostic Testing Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Melanoma Skin Cancer Diagnostic Testing Historic Market Size by Application (2018-2023)
3.2.2 Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Melanoma Skin Cancer Diagnostic Testing Revenue Breakdown by Application (2018-2029)
4 Melanoma Skin Cancer Diagnostic Testing Competition Analysis by Players
4.1 Global Melanoma Skin Cancer Diagnostic Testing Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Melanoma Skin Cancer Diagnostic Testing as of 2022)
4.3 Date of Key Players Enter into Melanoma Skin Cancer Diagnostic Testing Market
4.4 Global Top Players Melanoma Skin Cancer Diagnostic Testing Headquarters and Area Served
4.5 Key Players Melanoma Skin Cancer Diagnostic Testing Product Solution and Service
4.6 Competitive Status
4.6.1 Melanoma Skin Cancer Diagnostic Testing Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Myriad Genetics
5.1.1 Myriad Genetics Profile
5.1.2 Myriad Genetics Main Business
5.1.3 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.1.4 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.1.5 Myriad Genetics Recent Developments
5.2 Abbott Laboratories
5.2.1 Abbott Laboratories Profile
5.2.2 Abbott Laboratories Main Business
5.2.3 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.2.4 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.2.5 Abbott Laboratories Recent Developments
5.3 Foundation Medicine
5.3.1 Foundation Medicine Profile
5.3.2 Foundation Medicine Main Business
5.3.3 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.3.4 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.3.5 Pathway Genomics Corporation Recent Developments
5.4 Pathway Genomics Corporation
5.4.1 Pathway Genomics Corporation Profile
5.4.2 Pathway Genomics Corporation Main Business
5.4.3 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.4.4 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.4.5 Pathway Genomics Corporation Recent Developments
5.5 Cancer Genetics
5.5.1 Cancer Genetics Profile
5.5.2 Cancer Genetics Main Business
5.5.3 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.5.4 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.5.5 Cancer Genetics Recent Developments
5.6 Castle Biosciences
5.6.1 Castle Biosciences Profile
5.6.2 Castle Biosciences Main Business
5.6.3 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.6.4 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.6.5 Castle Biosciences Recent Developments
5.7 NeoGenomics
5.7.1 NeoGenomics Profile
5.7.2 NeoGenomics Main Business
5.7.3 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.7.4 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.7.5 NeoGenomics Recent Developments
5.8 Dermtech
5.8.1 Dermtech Profile
5.8.2 Dermtech Main Business
5.8.3 Dermtech Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.8.4 Dermtech Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.8.5 Dermtech Recent Developments
5.9 Sysmex Inostics
5.9.1 Sysmex Inostics Profile
5.9.2 Sysmex Inostics Main Business
5.9.3 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Products, Services and Solutions
5.9.4 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Revenue (US$ Million) & (2018-2023)
5.9.5 Sysmex Inostics Recent Developments
6 North America
6.1 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Melanoma Skin Cancer Diagnostic Testing Market Dynamics
11.1 Melanoma Skin Cancer Diagnostic Testing Industry Trends
11.2 Melanoma Skin Cancer Diagnostic Testing Market Drivers
11.3 Melanoma Skin Cancer Diagnostic Testing Market Challenges
11.4 Melanoma Skin Cancer Diagnostic Testing Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
